Article: Nicotinamide Riboside Protects the Heart from the Cardiotoxic Effects of Doxorubicin, a Chemotherapy Drug: Preclinical Findings

PrevNext
Cardiovascular Health Preclinical

Nicotinamide Riboside Protects the Heart from the Cardiotoxic Effects of Doxorubicin, a Chemotherapy Drug: Preclinical Findings

Synopsis

Doxorubicin (DOX) is a common chemotherapy drug, but it can seriously damage the heart, partly due to oxidative stress. Normally, heart cells use autophagy to remove damaged components and protect themselves, but DOX blocks this process, worsening heart injury. This study found that nicotinamide riboside (NR), a precursor to NAD+, can prevent DOX-induced heart damage. NR increased NAD+ levels, reduced heart injury, and improved heart function in mice, and it also protected cultured heart cells. NR worked by restoring autophagy, clearing damaged cellular components, reducing oxidative stress, and maintaining lysosome function. Blocking lysosome acidification or SIRT1 eliminated NR’s protective effects, showing that NR protects the heart via the NAD+/SIRT1 pathway.

Journal

Clinical Science

Share

Read more

Clinical

Nicotinamide Riboside Supplementation Increases NAD+ Levels in Humans: Clinical Findings

Objectives To evaluate the safety and efficiacy of NR supplementation in overweight, but otherwise healthy men and women. Journal Scientific Reports Key Outcomes NR supplementation significantly ...

Read more
Healthy Aging & Longevity

NAMPT Deficiency in Mouse Liver Cells Shows Minimal Impact on NAD+ and Mitochondrial Health: Preclinical Findings

Synopsis Supplementation with NAD+ precursors such as nicotinamide riboside (NR) has been shown to improve mitochondrial function and prevent liver fat accumulation in high-fat diet (HFD)-fed rode...

Read more